//May 25, 2023
Gaithersburg-based biotechnology company Hememics Biotechnologies Inc., developer of a handheld, multiplexed biosensor platform that can test antibodies, antigens and molecular targets simultaneously, Thursday announced the closing of a $2 million Seed 2 financing round.
Participants of this round include a strategic investor, existing investors and TEDCO, the Maryland Technology Development Corporation.
Hememics uses graphene-based sensors with its patented bio preservatives to bring handheld, lab-quality testing performance to wherever it is needed – whether it is a farm, emergency room or battlefield. Its platform consists of a portable, easy-to-use reader utilizing a single-use biochip with 32 sensors. Our sensors can be individually programmed to detect molecular, antigen and antibody targets.
-Sign up for your daily digest of Maryland News.
Erie Insurance sues Maryland Insurance Administration over finding of race discr[...]
9/6/2023
Moore appoints members to authority for sustaining thoroughbred horse racing
9/6/2023
Md. Bar Foundation presents awards, announces class of fellows
9/6/2023
Md. Board of Elections names successor to longtime administrator Lamone
8/6/2023
At MSBA, one panel asks whether non-lawyers can help improve access to justice
8/6/2023
Donald Trump described Pentagon plan of attack and shared classified map, indict[...]
9/6/2023
Trump indicted: What to know about the documents case and what’s next
9/6/2023
Lawyers blame ChatGPT for tricking them into citing bogus case law
9/6/2023
Supreme Court voting rights ruling stuns minority voters, who hope it expands th[...]
9/6/2023
Trump indicted in classified documents case in a historic first for a former pre[...]
8/6/2023
Submit an entry for the business calendar